Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells

Marta Coscia, MD, PhD, Micol Rigoni, PhD, Chiara Riganti, MD, Ivana Campia, PhD, Candida Vitale, MD, Valentina Griggio, PhD, Silvia Peola, PhD, Barbara Castella, PhD, Patrizia Sciancalepore, MD, Daniela Drandi, PhD, Marco Ladetto, MD, Amalia Bosia, MD, Mario Boccadoro, MD, Massimo Massaia, MD

Blood (2011) 118 (21): 735.

https://doi.org/10.1182/blood.V118.21.735.735

Published: 2011

Journal Articles

IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals

Marta Coscia, MD, PhD, Francesca Pantaleoni, PhD, Chiara Riganti, MD, Candida Vitale, MD, Micol Rigoni, PhD, Silvia Peola, PhD, Daniela Drandi, PhD, Barbara Castella, PhD, Marina Ruggeri, PhD, Paola Omedè, MD, Marco Ladetto, MD, Amalia Bosia, MD, Mario Boccadoro, MD, Massimo Massaia, MD

Blood (2010) 116 (21): 2431.

https://doi.org/10.1182/blood.V116.21.2431.2431

Published: 2010

Journal Articles

The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status

Marta Coscia, MD, PhD, Candida Vitale, MD, Silvia Peola, PhD, Chiara Riganti, MD, Daniela Angelini, PhD, Myriam Foglietta, MD, Francesca Pantaleoni, PhD, Giorgia Matta, MD, Sabina Chiaretti, MD, Anna Guarini, PhD, Daniela Drandi, PhD, Marco Ladetto, MD, Amalia Bosia, MD, Luca Battistini, MD, Robin Foà, MD, Mario Boccadoro, MD, Jean-Jacques Fournié, PhD, Massimo Massaia, MD

Blood (2010) 116 (21): 3602.

https://doi.org/10.1182/blood.V116.21.3602.3602

Published: 2010

Journal Articles

Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL)

Marta Coscia, MD, PhD, Michela Capello, PhD, Valentina Griggio, PhD, Federica Linty, PhD, Candida Vitale, MD, Silvia Peola, PhD, Barbara Castella, PhD, Micol Rigoni, PhD, Daniela Drandi, PhD, Marina Ruggeri, PhD, Paola Omedè, PhD, Marco Ladetto, MD, Franco Novelli, MD, Mario Boccadoro, MD, Massimo Massaia, MD

Blood (2010) 116 (21): 917.

https://doi.org/10.1182/blood.V116.21.917.917

Published: 2010

Journal Articles

Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.

Marta Coscia, MD, Francesca Pantaleoni, PhD, Chiara Riganti, MD, Micol Rigoni, PhD, Candida Vitale, MD, Silvia Peola, PhD, Daniela Drandi, Marco Ladetto, Amalia Bosia, MD, Mario Boccadoro, Massimo Massaia, MD

Blood (2009) 114 (22): 2333.

https://doi.org/10.1182/blood.V114.22.2333.2333

Published: 2009

Journal Articles

Phenotypic and Functional Features of Vγ9/Vδ2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells.

Marta Coscia, MD, Silvia Peola, PhD, Giorgia Matta, MD, Francesca Pantaleoni, PhD, Myriam Foglietta, MD, Daniela Angelini, PhD, Sabina Chiaretti, MD, Chiara Riganti, MD, Anna Guarini, PhD, Daniela Drandi, PhD, Marco Ladetto, MD, Amalia Bosia, MD, Robin Foà, MD, Luca Battistini, MD, Mario Boccadoro, MD, Jean Jacques Fournie, PhD, Massimo Massaia, MD

Blood (2007) 110 (11): 1131.

https://doi.org/10.1182/blood.V110.11.1131.1131

Published: 2007

NARROW

The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells

IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals

The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status

Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL)

Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.

Phenotypic and Functional Features of Vγ9/Vδ2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells.

Email alerts

ASH Publications

American Society of Hematology

The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells

IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals

The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status

Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL)

Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.

Phenotypic and Functional Features of Vγ9/Vδ2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only